The Trametinib trial for BRAF-Mutated Melanoma hits the NEJM this week. The difference in OS despite crossover is remarkable for a chemo/targeted trial, and speaks to how much promise this treatment has in this subset of patients.
Link:
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma: New England Journal of Medicine,
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment